U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Adenocarcinoma

MedGen UID:
1699198
•Concept ID:
C5204530
•
Neoplastic Process

Definition

An adenocarcinoma that does not respond to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Adenocarcinoma

Professional guidelines

PubMed

Effectiveness of erlotinib treatment in advanced KRAS mutation-negative lung adenocarcinoma patients: Results of a multicenter observational cohort study (MOTIVATE).
Sarosi V, Losonczy G, Francovszky E, Tolnay E, Torok S, Galffy G, Hegedus B, Dome B, Ostoros G
Lung Cancer 2014 Oct;86(1):54-8. Epub 2014 Jul 27 doi: 10.1016/j.lungcan.2014.07.011. PMID: 25129367
Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer.
Logothetis CJ, Samuels ML, von Eschenbach AC, Trindade A, Ogden S, Grant C, Johnson DE
J Clin Oncol 1983 Jun;1(6):368-79. doi: 10.1200/JCO.1983.1.6.368. PMID: 6422006
cis-Dichlorodiammineplatinum(II) for the treatment of advanced ovarian cancer.
Young RC, Von Hoff DD, Gormley P, Makuch R, Cassidy J, Howser D, Bull JM
Cancer Treat Rep 1979 Sep-Oct;63(9-10):1539-44. PMID: 387224

Recent clinical studies

Etiology

Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.
Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, Levine EG, Blumenstein BA, Vogelzang NJ
J Clin Oncol 2003 Apr 1;21(7):1232-7. doi: 10.1200/JCO.2003.06.100. PMID: 12663709
Phase II evaluation of didemnin B in hormonally refractory metastatic prostate cancer. A Southwest Oncology Group study.
Williamson SK, Wolf MK, Eisenberger MA, O'Rourke M, Brannon W, Crawford ED
Invest New Drugs 1995;13(2):167-70. doi: 10.1007/BF00872867. PMID: 8617581
Phase II study of ifosfamide and mesna in refractory adenocarcinoma of the endometrium. A Gynecologic Oncology Group study.
Sutton GP, Blessing JA, Homesley HD, McGuire WP, Adcock L
Cancer 1994 Mar 1;73(5):1453-5. doi: 10.1002/1097-0142(19940301)73:5<1453::aid-cncr2820730521>3.0.co;2-x. PMID: 8111713
Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate.
Pienta KJ, Redman B, Hussain M, Cummings G, Esper PS, Appel C, Flaherty LE
J Clin Oncol 1994 Oct;12(10):2005-12. doi: 10.1200/JCO.1994.12.10.2005. PMID: 7523606
Doxorubicin, mitomycin C and 5-fluorouracil in the treatment of hormone refractory adenocarcinoma of the prostate: a Southwest Oncology Group study.
Blumenstein B, Crawford ED, Saiers JH, Stephens RL, Rivkin SE, Coltman CA Jr
J Urol 1993 Aug;150(2 Pt 1):411-3. doi: 10.1016/s0022-5347(17)35496-4. PMID: 8326565

Diagnosis

Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480.
Ahles TA, Herndon JE 2nd, Small EJ, Vogelzang NJ, Kornblith AB, Ratain MJ, Stadler W, Palchak D, Marshall ME, Wilding G, Petrylak D, Holland JC; Cancer and Leukemia Group B
Cancer 2004 Nov 15;101(10):2202-8. doi: 10.1002/cncr.20655. PMID: 15484217
Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.
Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, Levine EG, Blumenstein BA, Vogelzang NJ
J Clin Oncol 2003 Apr 1;21(7):1232-7. doi: 10.1200/JCO.2003.06.100. PMID: 12663709
Reversal by transferrin of growth-inhibitory effect of suramin on hormone-refractory human prostate cancer cells.
Donat SM, Powell CT, Israeli RS, Fair WR, Heston WD
J Natl Cancer Inst 1995 Jan 4;87(1):41-6. doi: 10.1093/jnci/87.1.41. PMID: 7666462
Chemotherapy of hormone-refractory carcinoma of prostate with 5-fluorouracil, adriamycin, and mitomycin C.
Babaian RJ, Hsu SD
Urology 1984 Mar;23(3):272-5. doi: 10.1016/s0090-4295(84)90046-3. PMID: 6546626

Therapy

Vesicant characteristics of oxaliplatin following antecubital extravasation.
Kennedy JG, Donahue JP, Hoang B, Boland PJ
Clin Oncol (R Coll Radiol) 2003 Aug;15(5):237-9. doi: 10.1016/s0936-6555(02)00338-2. PMID: 12924452
5-fluorouracil and low-dose recombinant interferon-alpha-2a in patients with hormone-refractory adenocarcinoma of the prostate.
Shinohara N, Demura T, Matsumura K, Toyoda K, Kashiwagi A, Nagamori S, Ohmuro H, Ohzono S, Koyanagi T
Prostate 1998 Apr 1;35(1):56-62. doi: 10.1002/(sici)1097-0045(19980401)35:1<56::aid-pros8>3.0.co;2-f. PMID: 9537600
Phase II study of ifosfamide and mesna in refractory adenocarcinoma of the endometrium. A Gynecologic Oncology Group study.
Sutton GP, Blessing JA, Homesley HD, McGuire WP, Adcock L
Cancer 1994 Mar 1;73(5):1453-5. doi: 10.1002/1097-0142(19940301)73:5<1453::aid-cncr2820730521>3.0.co;2-x. PMID: 8111713
Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate.
Pienta KJ, Redman B, Hussain M, Cummings G, Esper PS, Appel C, Flaherty LE
J Clin Oncol 1994 Oct;12(10):2005-12. doi: 10.1200/JCO.1994.12.10.2005. PMID: 7523606
Adriamycin, 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU-NSC 409462), and cyclophosphamide in refractory adenocarcinoma of the breast and other tumors.
Presant CA, Kolhouse JF, Klahr C
Cancer 1976 Feb;37(2):620-8. doi: 10.1002/1097-0142(197602)37:2<620::aid-cncr2820370203>3.0.co;2-d. PMID: 1253101

Prognosis

Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.
Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, Levine EG, Blumenstein BA, Vogelzang NJ
J Clin Oncol 2003 Apr 1;21(7):1232-7. doi: 10.1200/JCO.2003.06.100. PMID: 12663709
Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate.
Pienta KJ, Redman B, Hussain M, Cummings G, Esper PS, Appel C, Flaherty LE
J Clin Oncol 1994 Oct;12(10):2005-12. doi: 10.1200/JCO.1994.12.10.2005. PMID: 7523606
Doxorubicin, mitomycin C and 5-fluorouracil in the treatment of hormone refractory adenocarcinoma of the prostate: a Southwest Oncology Group study.
Blumenstein B, Crawford ED, Saiers JH, Stephens RL, Rivkin SE, Coltman CA Jr
J Urol 1993 Aug;150(2 Pt 1):411-3. doi: 10.1016/s0022-5347(17)35496-4. PMID: 8326565
Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer.
Logothetis CJ, Samuels ML, von Eschenbach AC, Trindade A, Ogden S, Grant C, Johnson DE
J Clin Oncol 1983 Jun;1(6):368-79. doi: 10.1200/JCO.1983.1.6.368. PMID: 6422006
Adriamycin, 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU-NSC 409462), and cyclophosphamide in refractory adenocarcinoma of the breast and other tumors.
Presant CA, Kolhouse JF, Klahr C
Cancer 1976 Feb;37(2):620-8. doi: 10.1002/1097-0142(197602)37:2<620::aid-cncr2820370203>3.0.co;2-d. PMID: 1253101

Clinical prediction guides

Irinotecan plus bolus/infusional 5-Fluorouracil and leucovorin in patients with pretreated advanced pancreatic carcinoma: a multicenter experience of the Gruppo Oncologico Italia Meridionale.
Gebbia V, Maiello E, Giuliani F, Borsellino N, Arcara C, Colucci G
Am J Clin Oncol 2010 Oct;33(5):461-4. doi: 10.1097/COC.0b013e3181b4e3b0. PMID: 20142727
Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.
Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, Levine EG, Blumenstein BA, Vogelzang NJ
J Clin Oncol 2003 Apr 1;21(7):1232-7. doi: 10.1200/JCO.2003.06.100. PMID: 12663709
Phase II study of ifosfamide and mesna in refractory adenocarcinoma of the endometrium. A Gynecologic Oncology Group study.
Sutton GP, Blessing JA, Homesley HD, McGuire WP, Adcock L
Cancer 1994 Mar 1;73(5):1453-5. doi: 10.1002/1097-0142(19940301)73:5<1453::aid-cncr2820730521>3.0.co;2-x. PMID: 8111713
Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate.
Pienta KJ, Redman B, Hussain M, Cummings G, Esper PS, Appel C, Flaherty LE
J Clin Oncol 1994 Oct;12(10):2005-12. doi: 10.1200/JCO.1994.12.10.2005. PMID: 7523606
Adriamycin, 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU-NSC 409462), and cyclophosphamide in refractory adenocarcinoma of the breast and other tumors.
Presant CA, Kolhouse JF, Klahr C
Cancer 1976 Feb;37(2):620-8. doi: 10.1002/1097-0142(197602)37:2<620::aid-cncr2820370203>3.0.co;2-d. PMID: 1253101

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...